Company Overview
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
Key Highlights
- Biotechnology · Healthcare
- Led by Timothy Mark Dyer
- 3 employees
- Based in Geneva, GE
Price History
Loading…
Data from Twelve Data. Prices may be delayed.
Analyst Coverage
View All Coverage →No analyst coverage available.
Economic Calendar
View more →- Nov 12
Initial Jobless Claims
8:30 AM ET
Crypto Prices
View more →
Bitcoin (BTC)
71,271 −3.56%
Ethereum (ETH)
2,014 −1.94%
Solana (SOL)
82 −2.25%
Company Facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Geneva, GE, CH
- Incorporated
- Feb 12, 2020
- Website
- www.addextherapeutics.com
Latest SEC Filings
View All Filings →- Foreign Issuer Report (Form 6-K)Nov 12, 2026